{
    "organizations": [],
    "uuid": "a439ce076fad027011d64531716ac6a3e1fe0c8c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-orexigen-therapeutics-enters-agree/brief-orexigen-therapeutics-enters-agreement-for-sale-of-co-idUSFWN1S00ZO",
    "ord_in_thread": 0,
    "title": "BRIEF-Orexigen Therapeutics Enters Agreement For Sale Of Co",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 23, 2018 / 5:32 PM / Updated 27 minutes ago BRIEF-Orexigen Therapeutics Enters Agreement For Sale Of Co Reuters Staff April 23 (Reuters) - Orexigen Therapeutics Inc: * OREXIGEN THERAPEUTICS, INC. ENTERS AGREEMENT FOR SALE OF COMPANY * OREXIGEN THERAPEUTICS INC - ENTERED INTO ASSET PURCHASE DEAL WITH NALPROPION PHARMACEUTICALS, TO SELL SUBSTANTIALLY ALL OF ASSETS OF CO * OREXIGEN THERAPEUTICS INC - WILL SELL WORLD-WIDE RIGHTS TO CONTRAVE /MYSIMBA AND CERTAIN OTHER OREXIGEN ASSETS FOR $75 MILLION IN CASH * OREXIGEN THERAPEUTICS- NALPROPION PHARMACEUTICALS IS A NEWLY FORMED SPECIAL PURPOSE ENTITY CAPITALIZED BY INVESTOR GROUP INCLUDING PERNIX THERAPEUTICS Source text for Eikon: Further company coverage:",
    "published": "2018-04-23T20:32:00.000+03:00",
    "crawled": "2018-04-23T20:52:50.013+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "enters",
        "agreement",
        "sale",
        "co",
        "reuters",
        "staff",
        "april",
        "reuters",
        "orexigen",
        "therapeutic",
        "inc",
        "orexigen",
        "therapeutic",
        "enters",
        "agreement",
        "sale",
        "company",
        "orexigen",
        "therapeutic",
        "inc",
        "entered",
        "asset",
        "purchase",
        "deal",
        "nalpropion",
        "pharmaceutical",
        "sell",
        "substantially",
        "asset",
        "co",
        "orexigen",
        "therapeutic",
        "inc",
        "sell",
        "right",
        "contrave",
        "certain",
        "orexigen",
        "asset",
        "million",
        "cash",
        "orexigen",
        "nalpropion",
        "pharmaceutical",
        "newly",
        "formed",
        "special",
        "purpose",
        "entity",
        "capitalized",
        "investor",
        "group",
        "including",
        "pernix",
        "therapeutic",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}